Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Santen to Create New Exec Posts to Accelerate Globalization
March 13, 2014
- Novartis Japan Sales Tick Up 0.8%, Diovan Down 13%, Tasigna Up 35%
March 13, 2014
- Torii Confirms Positive Results from PII/III Study of Investigational Allergen Immunotherapy Treatment TO-203
March 13, 2014
- AstraZeneca, Osaka University Aim to Resurrect Ditched Drug Candidates
March 13, 2014
- 19 Pharmacy-Operating Companies Join Bidding Group for Drug Purchasing
March 12, 2014
- Announcement: 7th Annual Marketing Excellence Japan 2014 – Westin Tokyo, May 13 – 14
March 12, 2014
- Eisai to Forge Cross-Regional Biz Units for Oncology, Neurology in July
March 11, 2014
- Otsuka, UCB Japan File Partial Change Application for Monotherapy for E Keppra
March 11, 2014
- Ethical Drug Sales Up 4.7% in January Owing to Growth in Influenza-Related Products: Crecon Report
March 11, 2014
- Takeda Picks Third-Party Investigator for CASE-J Issue, Probe Expected to Take 3 Months
March 11, 2014
- Pfizer Japan Logs 1.2% Sales Increase in FY2013
March 10, 2014
- Eisai, Biogen Idec to Jointly Develop, Commercialize AD Treatments
March 10, 2014
- Asahi Kasei Pharma Exec Hori Picked as Next President
March 10, 2014
- Takeda Submits NDA for Once-Weekly DPP-4 Inhibitor Trelagliptin
March 10, 2014
- US Journal to Revise COI Disclosure in Article Used by Shionogi and Eli Lilly Japan to Promote Cymbalta
March 10, 2014
- 28% of Mainstays to Face New Price Cuts for Long-Listed Drugs: Jiho Survey
March 7, 2014
- Map Software Used to Reorganize MRs’ Marketing Territories Boosts Operating Efficiency at Pfizer Japan
March 7, 2014
- Five Generic Makers See Various Price Reduction Rates under FY2014 NHI Revision
March 6, 2014
- New Price Cuts for Long-Listed Drugs to Pummel MTPC, Astellas: Jiho Tally
March 6, 2014
- Santen Licenses Anti-Endoglin Antibodies from TRACON to Develop Novel Treatments for Retinal Diseases
March 6, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…